

## Literatur für onkologie heute 02/2021

### SCHWERPUNKT: GASTROINTESTINALE TUMOREN

#### **Das nicht-muskelinvasive Harnblasenkarzinom – Diagnostik, Therapie und Nachsorge (S. 43–54)**

*L. Eismann, Y. Volz, B. Schlenker, C. G. Stief, J. F. Jokisch*

1. Ferlay J et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015; 136(5): E359–86
2. DeGeorge KC, Holt HR, and Hodges SC. Bladder Cancer: Diagnosis and Treatment. *Am Fam Physician* 2017; 96(8): 507–14
3. Nadal R and Bellmunt J. Management of metastatic bladder cancer. *Cancer Treat Rev* 2019; 76: 10–21
4. Babjuk M et al. EAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS) 2018, in European Association of Urology Guidelines. 2018 Edition. 2018, European Association of Urology Guidelines Office: Arnhem, The Netherlands
5. Witjes JA et al. EAU Guidelines on Muscle-invasive and metastatic Bladder Cancer 2018, in European Association of Urology Guidelines. 2018 Edition. 2018, European Association of Urology Guidelines Office: Arnhem, The Netherlands
6. Leal J et al. Economic Burden of Bladder Cancer Across the European Union. *Eur Urol*, 2016; 69(3): 438–47
7. Richters A, Aben KKH, and Kiemeny LALM. The global burden of urinary bladder cancer: an update. *World J Urol* 2020; 38(8): 1895–904
8. Negri E and La Vecchia C. Epidemiology and prevention of bladder cancer. *Eur J Cancer Prev* 2001; 10(1): 7–14
9. Crawford JM. The origins of bladder cancer. *Laboratory Investigation* 2008; 88(7): 686–693
10. Brandau S and Böhle A. Bladder cancer. I. Molecular and genetic basis of carcinogenesis. *Eur Urol* 2001; 39(5): 491–7
11. Manley KV et al. Risk factors for development of primary bladder squamous cell carcinoma. *Ann R Coll Surg Engl* 2017; 99(2): 155–60
12. Aron M. Variant Histology in Bladder Cancer – Current Understanding of Pathologic Subtypes. *Curr Urol Rep* 2019; 20(12): 80
13. Niedworok C. Urachal Carcinoma of the Bladder: Impact of Clinical and Immunohistochemical Parameters on Prognosis. *J Urol* 2016; 195(6): 1690–6
14. Behrendt MA and van Rhijn BWG. Genetics and biological markers in urachal cancer. *Transl Androl Urol* 2016; 5(5): 655–61
15. Burger M et al. Epidemiology and risk factors of urothelial bladder cancer. *Eur Urol* 2013; 63(2): 234–41
16. Lammers RJ et al. Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer. *Eur Urol* 2011; 60(4): 713–20
17. Suriano F et al. Bladder cancer after radiotherapy for prostate cancer. *Rev Urol* 2013; 15(3): 108–12
18. Janković S and Radosavljević V. Risk factors for bladder cancer. *Tumori* 2007; 93(1): 4–12
19. Mainz A. DEGAM S1-Handlungsempfehlung: Nicht sichtbare Hämaturie (NSH). AWMF online, 2019. 2.1
20. Davis R et al. Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. *J Urol* 2012; 188(6 Suppl): 2473–81

21. Satasivam P et al. The effect of oral anticoagulation on the prevalence and management of haematuria in a contemporary Australian patient cohort. *BJU Int* 2012; 110 Suppl 4: 80–4
22. Shephard EA et al. Clinical features of bladder cancer in primary care. *Br J Gen Pract* 2012; 62(602): e598–e604
23. Matulewicz RS et al. Dipstick Urinalysis as a Test for Microhematuria and Occult Bladder Cancer. *Bladder Cancer* 2017; 3: 45–49
24. Cavanaugh C and Perazella MA. Urine Sediment Examination in the Diagnosis and Management of Kidney Disease: Core Curriculum 2019. *Am J Kidney Dis* 2019; 73(2): 258–72
25. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms, Langversion 2.0, 2020, AWMF-Registrierungsnummer 032/038OL. <https://www.leitlinienprogramm-onkologie.de/leitlinien/harnblasenkarzinom/>. (Zugegriffen: 08.02.2021)
26. Oliveira MCd et al. Urinary Biomarkers in Bladder Cancer: Where Do We Stand and Potential Role of Extracellular Vesicles. *Cancers* 2020; 12(6): 1400
27. Lin T et al. Prospective evaluation of fluorescence in situ hybridization for diagnosing urothelial carcinoma. *Oncol Lett* 2017; 13(5): 3928–34
28. Zhu C-Z et al. A review on the accuracy of bladder cancer detection methods. *J Cancer* 2019; 10(17): 4038–44
29. Jokisch F et al. Prospective evaluation of 4-D contrast-enhanced-ultrasound (CEUS) imaging in bladder tumors. *Clin Hemorheol Microcirc* 2020; 74(1): 1–12
30. Rouprêt M et al. EAU Guidelines on Upper Urinary Tract Urothelial Carcinoma 2018, in European Association of Urology Guidelines. 2018 Edition. 2018, European Association of Urology Guidelines Office: Arnhem, The Netherlands
31. Galgano SJ et al. The Role of Imaging in Bladder Cancer Diagnosis and Staging. *Diagnostics (Basel, Switzerland)* 2020; 10(9): 703
32. Panebianco V et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). *Eur Urol* 2018; 74(3): 294–306
33. Vind-Kezunovic S et al. Detection of Lymph Node Metastasis in Patients with Bladder Cancer using Maximum Standardised Uptake Value and (18)F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: Results from a High-volume Centre Including Long-term Follow-up. *Eur Urol Focus* 2019; 5(1): 90–6
34. Sylvester RJ et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. *Eur Urol* 2006; 49(3): 466–5; discussion 475–7
35. Fernandez-Gomez J et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. *J Urol* 2009; 182(5): 2195–203
36. Sylvester RJ et al. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. *Eur Urol* 2021; S0302-2838(20)31019-8
37. Mowatt G et al. Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis. *Int J Technol Assess Health Care* 2011; 27(1): 3–10
38. Burger M et al. Photodynamic Diagnosis of Non-muscle-invasive Bladder Cancer with Hexaminolevulinat Cystoscopy: A Meta-analysis of Detection and Recurrence Based on Raw Data. *Eur Urol* 2013; 64(5): 846–54

39. Kang W et al. Narrow band imaging-assisted transurethral resection reduces the recurrence risk of non-muscle invasive bladder cancer: A systematic review and meta-analysis. *Oncotarget* 2017; 8(14): 23880–90
40. Heijden A and Witjes J. Recurrence, Progression, and Follow-Up in Non-Muscle-Invasive Bladder Cancer. *Eur Urol Suppl* 2009; 8(7): 556–62
41. Sylvester RJ, Oosterlinck W and van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. *J Urol* 2004; 171(6): 2186–90, quiz 2435
42. Messing EM et al. Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. *JAMA* 2018; 319(18): 1880–88
43. Jokisch JF, Karl A and Stief C. Intravesical immunotherapy in nonmuscle invasive bladder cancer. *Indian J Urol* 2015; 31(4): 304–11
44. Di Stasi SM et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. *Lancet Oncol* 2006; 7(1): 43–51
45. Rentsch CA et al. Bacillus Calmette-Guérin Strain Differences Have an Impact on Clinical Outcome in Bladder Cancer Immunotherapy. *Eur Urol* 2014; 66(4): 677–88
46. Boehm BE et al. Efficacy of bacillus Calmette-Guérin Strains for Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Network Meta-Analysis. *J Urol* 2017; 198(3): 503–10
47. Brausi M et al. Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. *Eur Urol* 2014; 65(1): 69–76
48. Oddens J et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. *Eur Urol* 2013; 63(3): 462–72
49. Sylvester RJ et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. *Eur Urol* 2010; 57(5): 766–73
50. Lamm DL et al. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. *J Urol* 2000; 163(4): 1124–9
51. Kramer MW et al. Current Evidence of Transurethral En-bloc Resection of Nonmuscle Invasive Bladder Cancer. *Eur Urol Focus* 2017; 3(6): 567–76
52. Nagele U et al. Waterjet hydrodissection: first experiences and short-term outcomes of a novel approach to bladder tumor resection. *World J Urol* 2011; 29(4): 423–27
53. Sousa A et al. Recirculant hyperthermic IntraVESical chemotherapy (HIVEC) in intermediate - high-risk non-muscle-invasive bladder cancer. *Int J Hyperthermia* 2016; 32(4): 374–80
54. De Santis M et al. A phase III, randomized, open-label, multicenter, global study of durvalumab and bacillus calmette-guérin (BCG) versus BCG alone in high-risk, BCG-naïve non-muscle-invasive bladder cancer (NMIBC) patients (POTOMAC). *J Clin Oncol* 2019; 37(7\_suppl): TPS500–TPS500
55. Kamat AM et al. KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC. *Future Oncol* 2020; 16(10): 507–16
56. Balar AV et al. Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG). *J Clin Oncol* 2019; 37(7\_suppl): 350

57. Black PC et al. Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816). *J Clin Oncol* 2020; 38(15\_suppl): 5022
58. Holmang S and Johansson SL. Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression. *J Urol* 2002; 167(4): 1634–7
59. Palou J et al. Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. *J Urol* 2005; 174(3): 859–61; discussion 861
60. Kamat AM et al. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. *BJU Int* 2011; 108(7): 1119–23